Option chain shows key data for Embecta's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Embecta.

Embecta (NASDAQ:EMBC) Stock, Option Chain

Embecta

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Earnings

Earnings Beats

Fintech news covering the emerging Financial Technology services sector

Fintech

Mid Cap

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

EMBC

Embecta Corp. (NASDAQ: EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items.

Embecta Corp. Tops Q3 Earnings and Revenue Estimates

4. Hormone Replacement Therapy (HRT)

Health Care

Rumors

General

Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company&#39;s U.S. business has struggled with the rise of GLP-1 drugs and declining margins.

Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

movers image

Intraday Update

Movers

APLD

ATPC

AVAH

CMAX

CRWD

DOGZ

FTEL

KARO

LGCB

LPSN

MEDS

MEIP

MIRA

MNSO

NCPL

NUKK

NWGL

PRTG

PSIG

RYAAY

SAVA

SERV

SLNA

SLRX

SNOA

SOPA

TELL

TKNO

VIRI

XCUR

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Embecta Corp

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Thursday potentially following the company's recent announcement about its Bitcoin (CRYPTO: BTC/USD) activity, capital markets updates and performance indicators. Here&#8217;s <a href="https://www.benzinga.com/quote/SMLR/news">what you need to know.</a>
What To Know: Multiple crypto-linked stocks are moving higher on Thursday after Bitcoin hit <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">new all-time highs</a> above $98,000. Some names are outperforming and it appears to be a result of recent Bitcoin accumulation strategies. 
MicroStrategy and MARA Holdings have <a href="https://www.benzinga.com/news/offerings/24/11/42112653/bitcoin-mining-stock-mara-holdings-is-outpacing-peers-whats-going-on">outperformed peers</a> in recent trading sessions. Both companies recently completed offerings and used the proceeds to buy additional Bitcoin as they focus on stockpiling.
Semler Scientific has also adopted a Bitcoin treasury strategy. The company announced it raised $21.5 million through the sale of 505,544 shares of its common stock under an at-the-market offering earlier this week. The proceeds partially funded the company&#8217;s recent Bitcoin purchases.
Semler said it purchased 215 Bitcoin for $17.7 million in cash at an average price of $82,502 between Nov. 6 and Nov. 15. The company now holds a total of 1,273 Bitcoin, acquired for a total cost of $88.7 million.
The rise in Semler's stock price suggests investors are optimistic about the company's strategic use of equity to expand its Bitcoin holdings.
SMLR Price Action: Semler Scientific shares were up 18.9% at $70.50 at the time of publication, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116475/paying-6-24-million-for-a-duct-taped-banana-justin-sun-did-just-that-and-now-hell-eat-it-as-part-of-this-unique-artistic-experience">Paying $6.24 Million For A Duct-Taped Banana? Justin Sun Did Just That — And Now He&#8217;ll Eat It &#8216;As Part Of This Unique Artistic Experience&#8217;</a></li>
</ul>
Image Via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

SMLR

Semler Scientific Stock Is Surging Thursday: What's Going On?

Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and raises the price target from $22 to $25.

Price Target

Barrington Research Maintains Outperform on Universal Technical, Raises Price Target to $25

SNOW

Live On CNBC, Stephanie Link Announces Bought More Snowflake

Court's Decision Rejects Nano's Shameless and Desperate Attempt to Disenfranchise Shareholders By Claiming ADS Holders Have No Rights
Murchinson is Pleased with the Court's Ruling and Will Continue its Efforts to Improve Nano's Broken Corporate Governance, Halt the Pattern of Hypocritical Actions and Protect All Shareholders' Interests Through Current Proxy Contest
Murchinson Urges Nano's Board to Comply with the Court's Decision Immediately and Avoid Costly Legal Maneuvers or Other Attempts to Evade Implementing What Shareholders Voted For
Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.1% of the outstanding shares of Nano Dimension Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) ("Nano" or the "Company") today announced that, on November 21, 2024, the District Court for the Central District in Israel (the "Court") delivered its long-awaited decision regarding the results of the Nano special meeting held in March 2023 (the "March 2023 EGM"). The Court has fully validated the results of the March 2023 EGM.
At the March 2023 EGM, shareholders overwhelmingly supported all of Murchinson's proposals to:
<ul>
<li>Amend the Articles of Association of Nano to allow shareholders to fill vacancies on the Board of Directors (the "Board"). This right was previously available only to the Board.</li>
<li>Amend the Articles of Association of Nano to allow shareholders to remove directors from the Board at any general meeting and via a simple majority. Previously, shareholders had no such right to hold directors accountable between annual meetings and could only do so with a special majority.</li>
<li>Remove four then-serving directors: Yoav Stern, Yoav Nissan-Cohen, Oded Gera and Igal Rotem. Notably, Mr. Rotem has since resigned from the Board, but Messrs. Stern, Nissan-Cohen and Gera continued to serve on the Board.</li>
<li>Install two independent and highly-qualified professionals on the Board: Kenneth Traub and Dr. Joshua Rosensweig.</li>
</ul>
The Court's decision confirms that Mr. Traub and Dr. Rosensweig are full members of the Board, and that Messrs. Stern, Nissan-Cohen and Gera were lawfully removed from the Board at the March 2023 EGM.

Legal

NNDM

Israeli District Court Rules In Favor Of Murchinson And Validates Shareholder Vote From The Nano Dimension March 2023 Special Meeting; Says "Murchinson Urges Nano's Board To Comply With The Court's Decision Immediately And Avoid Costly Legal Maneuvers Or Other Attempts To Evade Implementing What Shareholders Voted For"

Stifel analyst Lars Kjellberg initiates coverage on Mativ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATV#NYSE">MATV</a>) with a Hold rating and announces Price Target of $15.5.

Initiation

MATV

Stifel Initiates Coverage On Mativ Holdings with Hold Rating, Announces Price Target of $15.5

Tigress Financial analyst Ivan Feinseth maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and raises the price target from $24 to $26.

LYFT

Tigress Financial Maintains Buy on Lyft, Raises Price Target to $26

Stifel analyst Mark Astrachan maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Hold and lowers the price target from $165 to $137.

Stifel Maintains Hold on Target, Lowers Price Target to $137

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.00</td>
<td>$469.4K</td>
<td>48.2K</td>
<td>6.5K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$305.00</td>
<td>$55.1K</td>
<td>442</td>
<td>2.1K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$72.50</td>
<td>$42.2K</td>
<td>13.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$242.50</td>
<td>$34.0K</td>
<td>369</td>
<td>537</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$37.00</td>
<td>$44.0K</td>
<td>1.0K</td>
<td>415</td>
</tr>
<tr>
<td>FOUR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$110.00</td>
<td>$33.5K</td>
<td>241</td>
<td>242</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$200.00</td>
<td>$71.6K</td>
<td>0</td>
<td>204</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$43.2K</td>
<td>46</td>
<td>176</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For SOFI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), we notice a call option sweep that happens to be bearish, expiring in 421 day(s) on January 16, 2026. This event was a transfer of 1005 contract(s) at a $15.00 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $469.4K, with a price of $464.0 per contract. There were 48240 open contracts at this strike prior to today, and today 6580 contract(s) were bought and sold. 
• Regarding COIN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), we observe a call option trade with bullish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 50 contract(s) at a $305.00 strike. The total cost received by the writing party (or parties) was $55.1K, with a price of $1103.0 per contract. There were 442 open contracts at this strike prior to today, and today 2179 contract(s) were bought and sold. 
• Regarding C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), we observe a call option trade with bearish sentiment. It expires in 211 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $42.2K, with a price of $422.0 per contract. There were 13181 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For JPM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), we notice a call option sweep that happens to be bearish, expiring in 8 day(s) on November 29, 2024. This event was a transfer of 100 contract(s) at a $242.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $341.0 per contract. There were 369 open contracts at this strike prior to today, and today 537 contract(s) were bought and sold. 
• Regarding LMND (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>), we observe a put option trade with neutral sentiment. It expires in 57 day(s) on January 17, 2025. Parties traded 200 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $220.0 per contract. There were 1003 open contracts at this strike prior to today, and today 415 contract(s) were bought and sold. 
• Regarding FOUR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), we observe a call option trade with bullish sentiment. It expires in 57 day(s) on January 17, 2025. Parties traded 50 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $33.5K, with a price of $670.0 per contract. There were 241 open contracts at this strike prior to today, and today 242 contract(s) were bought and sold. 
• Regarding BX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), we observe a put option trade with bearish sentiment. It expires in 92 day(s) on February 21, 2025. Parties traded 47 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $71.6K, with a price of $1525.0 per contract. There were 0 open contracts at this strike prior to today, and today 204 contract(s) were bought and sold. 
• For AFRM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), we notice a put option sweep that happens to be bearish, expiring in 211 day(s) on June 20, 2025. This event was a transfer of 48 contract(s) at a $55.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $43.2K, with a price of $900.0 per contract. There were 46 open contracts at this strike prior to today, and today 176 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AFRM

COIN

FOUR

LMND

SOFI

8 Financials Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$360.00</td>
<td>$33.6K</td>
<td>22.5K</td>
<td>44.3K</td>
</tr>
<tr>
<td>AMZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$195.00</td>
<td>$181.5K</td>
<td>9.4K</td>
<td>13.9K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$108.00</td>
<td>$26.8K</td>
<td>1.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$76.8K</td>
<td>7.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.00</td>
<td>$106.5K</td>
<td>78</td>
<td>1.0K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.00</td>
<td>$134.5K</td>
<td>2.3K</td>
<td>494</td>
</tr>
<tr>
<td>FL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$22.00</td>
<td>$40.8K</td>
<td>402</td>
<td>400</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$80.00</td>
<td>$33.3K</td>
<td>295</td>
<td>305</td>
</tr>
<tr>
<td>MMYT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$125.00</td>
<td>$25.3K</td>
<td>8</td>
<td>161</td>
</tr>
<tr>
<td>PTON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$10.00</td>
<td>$37.5K</td>
<td>408</td>
<td>150</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 350 contract(s) at a $360.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $96.0 per contract. There were 22567 open contracts at this strike prior to today, and today 44374 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 1261 contract(s) at a $195.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $181.5K, with a price of $144.0 per contract. There were 9445 open contracts at this strike prior to today, and today 13975 contract(s) were bought and sold. 
• Regarding PDD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 80 contract(s) at a $108.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.8K, with a price of $335.0 per contract. There were 1878 open contracts at this strike prior to today, and today 1764 contract(s) were bought and sold. 
• For MBLY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), we notice a call option trade that happens to be bullish, expiring in 57 day(s) on January 17, 2025. This event was a transfer of 233 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $330.0 per contract. There were 7128 open contracts at this strike prior to today, and today 1186 contract(s) were bought and sold. 
• For XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we notice a call option sweep that happens to be bearish, expiring in 120 day(s) on March 21, 2025. This event was a transfer of 500 contract(s) at a $12.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $213.0 per contract. There were 78 open contracts at this strike prior to today, and today 1086 contract(s) were bought and sold. 
• Regarding GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), we observe a call option sweep with bearish sentiment. It expires in 120 day(s) on March 21, 2025. Parties traded 272 contract(s) at a $55.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $134.5K, with a price of $495.0 per contract. There were 2392 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding FL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), we observe a call option sweep with bearish sentiment. It expires in 15 day(s) on December 6, 2024. Parties traded 160 contract(s) at a $22.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.8K, with a price of $255.0 per contract. There were 402 open contracts at this strike prior to today, and today 400 contract(s) were bought and sold. 
• For BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we notice a call option trade that happens to be bullish, expiring in 147 day(s) on April 17, 2025. This event was a transfer of 30 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $33.3K, with a price of $1110.0 per contract. There were 295 open contracts at this strike prior to today, and today 305 contract(s) were bought and sold. 
• Regarding MMYT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>), we observe a call option sweep with bullish sentiment. It expires in 92 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $125.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.3K, with a price of $550.0 per contract. There were 8 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• For PTON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>), we notice a put option trade that happens to be bearish, expiring in 147 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $250.0 per contract. There were 408 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

BABA

MBLY

MMYT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PTON

TSLA

XPEV

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Information Technology sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$155.00</td>
<td>$45.1K</td>
<td>174.0K</td>
<td>260.1K</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$30.00</td>
<td>$36.3K</td>
<td>33.8K</td>
<td>43.0K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$227.50</td>
<td>$54.2K</td>
<td>14.2K</td>
<td>30.6K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$550.00</td>
<td>$31.2K</td>
<td>4.7K</td>
<td>12.2K</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$167.50</td>
<td>$38.5K</td>
<td>1.9K</td>
<td>12.1K</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$360.00</td>
<td>$138.9K</td>
<td>3.4K</td>
<td>3.0K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$136.00</td>
<td>$109.2K</td>
<td>2.5K</td>
<td>2.5K</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.00</td>
<td>$26.0K</td>
<td>2.6K</td>
<td>2.2K</td>
</tr>
<tr>
<td>IONQ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$28.00</td>
<td>$98.2K</td>
<td>5.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$150.00</td>
<td>$27.0K</td>
<td>1.1K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 4029 contract(s) at a $155.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $45.1K, with a price of $11.0 per contract. There were 174065 open contracts at this strike prior to today, and today 260113 contract(s) were bought and sold. 
• Regarding SMCI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), we observe a call option sweep with bullish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 300 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.3K, with a price of $121.0 per contract. There were 33874 open contracts at this strike prior to today, and today 43077 contract(s) were bought and sold. 
• Regarding AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we observe a call option sweep with bullish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 217 contract(s) at a $227.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $250.0 per contract. There were 14297 open contracts at this strike prior to today, and today 30643 contract(s) were bought and sold. 
• For MSTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), we notice a call option trade that happens to be bullish, expiring in 1 day(s) on November 22, 2024. This event was a transfer of 50 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $31.2K, with a price of $624.0 per contract. There were 4751 open contracts at this strike prior to today, and today 12223 contract(s) were bought and sold. 
• Regarding SNOW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), we observe a call option trade with bullish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 100 contract(s) at a $167.50 strike. The total cost received by the writing party (or parties) was $38.5K, with a price of $385.0 per contract. There were 1912 open contracts at this strike prior to today, and today 12121 contract(s) were bought and sold. 
• For CRM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), we notice a call option sweep that happens to be bullish, expiring in 29 day(s) on December 20, 2024. This event was a transfer of 142 contract(s) at a $360.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $138.9K, with a price of $977.0 per contract. There were 3442 open contracts at this strike prior to today, and today 3041 contract(s) were bought and sold. 
• Regarding AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), we observe a put option sweep with bearish sentiment. It expires in 8 day(s) on November 29, 2024. Parties traded 473 contract(s) at a $136.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $109.2K, with a price of $231.0 per contract. There were 2543 open contracts at this strike prior to today, and today 2546 contract(s) were bought and sold. 
• For RCAT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>), we notice a call option sweep that happens to be bearish, expiring in 29 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $8.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $26.0K, with a price of $130.0 per contract. There were 2673 open contracts at this strike prior to today, and today 2236 contract(s) were bought and sold. 
• Regarding IONQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), we observe a put option trade with bearish sentiment. It expires in 29 day(s) on December 20, 2024. Parties traded 390 contract(s) at a $28.00 strike. The total cost received by the writing party (or parties) was $98.2K, with a price of $252.0 per contract. There were 5055 open contracts at this strike prior to today, and today 2096 contract(s) were bought and sold. 
• Regarding DDOG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), we observe a call option sweep with bullish sentiment. It expires in 8 day(s) on November 29, 2024. Parties traded 227 contract(s) at a $150.00 strike. This particular call needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $119.0 per contract. There were 1101 open contracts at this strike prior to today, and today 1472 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

DDOG

IONQ

MSTR

NVDA

RCAT

SMCI

10 Information Technology Stocks With Whale Alerts In Today's Session

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Stifel analyst Erik Rasmussen maintains Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) with a Buy and raises the price target from $195 to $205.

Stifel Maintains Buy on Digital Realty Trust, Raises Price Target to $205

Macro Economic Events

Economics

Federal Reserve

Citadel's Griffin Says The U.S. Does Not Have Fiscal Room To Cut Taxes; Inflation Is Running Hotter Than Desired

On CNBC, Fed's Williams Forecasts Potential Growth At 2.25%-2.5%, Up From 2.0%

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining by more than 400 points on Thursday.
The Dow traded up 1.03% to 43,855.97 while the NASDAQ fell 0.10% to 18,948.11. The S&amp;P 500 also rose, gaining, 0.41% to 5,941.38.
Check This Out: <a href="https://www.benzinga.com/24/11/42086207/jim-cramer-likes-devon-energy-but-says-this-energy-stock-is-far-superior-to-devon">Jim Cramer Likes Devon Energy, But Calls Another Stock &#8216;Far Superior</a>&#8216;
Leading and Lagging Sectors Energy shares rose by 1.5% on Thursday.
In trading on Thursday, communication services shares fell by 2.7%.
Top Headline
Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) reported better-than-expected earnings for its fourth quarter.
The company posted a fourth-quarter net sales and revenue decline of 28% year-over-year to $11.143 billion, beating the consensus of $9.335 billion. Deere clocked an EPS of $4.55, down from $8.26 YoY, beating the consensus of $3.90
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares shot up 29% to $4.75. Quantum Computing announced it received another purchase order for its photonic chip foundry.</li>
<li>Shares of Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) got a boost, surging 32% to $169.90 after the company reported stronger-than-expected results for its third quarter. Snowflake expects fourth-quarter product revenue in the range of $906 million to $911 million, up approximately 23% year-over-year. The company also raised its full-year product revenue guidance from $3.356 billion to $3.43 billion, representing 29% year-over-year growth.</li>
<li>Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) shares were also up, gaining 19% to $23.60 after the company posted upbeat quarterly earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cool Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>) shares dropped 16% to $8.91 following third-quarter results.</li>
<li>Shares of Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) were down 46% to $2.0650 after the company announced PYX-201 clinical Phase 1 part 1 data.</li>
<li>Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) was down, falling 38% to $9.87. Kura Oncology and Kyowa Kirin disclosed a global strategic collaboration to develop and commercialize Ziftomenib in Acute Leukemias.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $69.61 while gold traded up 0.7% at $2,670.90.
Silver traded down 0.3% to $30.910 on Thursday, while copper fell 0.5% to $4.1340.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.15%, Germany's DAX gained 0.46% and France's CAC 40 rose 0.05%. Spain's IBEX 35 Index rose 0.02%, while London's FTSE 100 gained 0.57%.
Consumer confidence in the Eurozone fell by 1.2 points to a reading of -13.7 in November.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 falling 0.85%, Hong Kong's Hang Seng Index falling 0.53%, China's Shanghai Composite Index gaining 0.07% and India's BSE Sensex falling 0.54%.
Economics
<ul>
<li>U.S. existing home sales gained by 3.5% from the previous month to an annualized rate of 3.96 million in October.</li>
<li>The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8.</li>
<li>U.S. initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42112636/top-3-tech-stocks-which-could-rescue-your-portfolio-in-q4">Top 3 Tech Stocks Which Could Rescue Your Portfolio In Q4</a></li>
</ul>

Equities

Eurozone

Commodities

CLCO

KURA

PYXS

QUBT

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings

Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/ROST/earnings">closing bell on Thursday, Nov. 21.</a>
Analysts expect the Dublin, California-based bank to report quarterly earnings at $1.4 per share, up from $1.33 per share in the year-ago period. Ross Stores projects to report revenue of $5.15 billion for the recent quarter, compared to $4.92 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Oct. 28, Ross Stores named James Conroy, a seasoned retail CEO, as Chief Executive Officer, succeeding Barbara Rentler effective Feb. 2, 2025.
Ross Stores shares rose 0.1% to close at $139.32 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846f34dee7bf6000154d138/john-kernan">TD Cowen analyst John Kernan</a> maintained a Buy rating and cut the price target from $185 to $177 on Nov. 19. This analyst has an accuracy rate of 71%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Overweight rating and slashed the price target from $175 to $165 on Nov. 14. This analyst has an accuracy rate of 71%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b6cbc2b85e9300014425bc/paul-lejuez">Citigroup analyst Paul Lejuez</a> downgraded the stock from Buy to Neutral and cut the price target from $179 to $152 on Nov. 12. This analyst has an accuracy rate of 62%.</li>
<li>Morgan Stanley analyst Alex Straton maintained an Overweight rating and increased the price target from $163 to $178 on Aug. 23. This analyst has an accuracy rate of 64%.</li>
<li>UBS analyst Jay Sole maintained a Neutral rating and boosted the price target from $147 to $167 on Aug. 23. This analyst has an accuracy rate of 73%.</li>
</ul>
Considering buying ROST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/2f2567f9-7483-4558-97d9-844354a79b27" alt="" style="width:664px;height:auto" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42094434/top-3-consumer-stocks-that-are-ticking-portfolio-bombs">Top 3 Consumer Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

ROST

Ross Stores Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Thursday.</a>
The U.S. Department of the Treasury&#8217;s Bureau of the Fiscal Service has appointed BNY Mellon as the financial agent for the<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42116834/bny-to-manage-u-s-department-of-the-treasurys-largest-prepaid-debit-card-program-for-federal-benef" rel="noreferrer noopener"> Direct Express prepaid debit card program.</a>
This five-year agreement, which begins on January 3, will provide secure and easy access to federal benefit payments for approximately 3.4 million Americans.
BNY Mellon was selected after a comprehensive evaluation of proposals from multiple financial institutions.
The Treasury chose BNY Mellon for its wide range of customer service options that cater specifically to the unique needs of the Direct Express cardholders. These services include online and digital funds access, bill payment, cardless ATM access, omni-channel customer service through chat and text, and in-person authentication options.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/24/11/42117093/european-stability-may-improve-with-trumps-peace-through-strength-policy" rel="noreferrer noopener">European Stability May Improve With Trump&#8217;s &#8216;Peace Through Strength&#8217; Policy</a>
Additionally, the program will benefit from features such as contactless payment capabilities and emergency fund access.
Jennifer Barker, Global Head of Treasury Services at BNY Mellon, said, &#8220;We&#8217;re honored to be appointed as the financial agent for the Direct Express program, a decision which speaks to BNY&#8217;s legacy serving clients and communities throughout the financial ecosystem.&#8221;
Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) will continue its role as the program&#8217;s payment network, a position it has held since Direct Express was launched in 2008.
Other providers involved in the program include Galileo Financial Technologies, MoCaFi, Senture, Sunrise Banks, and Ubiquity Global Services.
The expanded services and customer-focused enhancements will help elevate the experience for Direct Express cardholders, ensuring they have easy access to their federal benefits.
Price Action: BK shares are trading higher by 0.73% to $78.44 at last check Thursday.
Image: Shutterstock/ Geobor
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42113449/natural-gas-prices-spike-to-over-1-year-highs-oil-surges-to-70-as-russia-fires-intercontinental-ballistic-missile-to-ukraine" target="_blank" rel="noreferrer noopener">Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia</a></li>
</ul>

Contracts

BNY Mellon Chosen To Oversee US Treasury's Direct Express Program - What's On the Cards?

B. Riley Securities analyst Naved Khan maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $190 to $220.

B. Riley Securities Maintains Buy on Wix.com, Raises Price Target to $220

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) analysts highlight the company's strong beat in the third quarter and guidance in the fourth quarter that may leave investors less confident in <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">the short term.</a>
The NVDA Analysts: Cantor Fitzgerald analyst C.J. Muse reiterated an Overweight rating on Nvidia with a $175 price target.
JPMorgan analyst Harlan Sur reiterated an Overweight rating and raised the price target from $155 to $170.
Oppenheimer analyst Rick Schafer reiterated an Outperform rating with a $175 price target.
Goldman Sachs analyst Toshiya Hari reiterated a Buy rating and raised the price target from $150 to $165.
Piper Sandler analyst Harsh Kumar reiterated an Overweight rating with a $175 price target.
Needham analyst Quinn Bolton reiterated a Buy rating and raised the price target from $145 to $160.
Benchmark analyst Cody Acree reiterated a Buy rating and raised the price target from $170 to $190.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors">Nvidia Slides During Thursday Pre-Market Despite Beating Q3 Estimates: &#8216;Even Outstanding Isn&#8217;t Enough For Some Investors&#8217;</a>
Cantor on NVDA: Fourth-quarter guidance coming in lower than estimates and gross margin guidance spooked investors in after-hours trading Muse said in a new investor note.
Muse said there was good and great news from Nvidia in the earnings report and conference call.
"The Blackwell cycle is tracking better than the original ~$3B guide for the January Q and is expected to accelerate much more meaningfully throughout CY25 and beyond with shortages anticipated over the next several Q's amidst ‘staggering demand,'" Muse said.
The analyst said they expect first-quarter revenues to "accelerate more meaningfully," which supports the bull case for $5.50 in earnings per share in calendar year 2025 and the potential for $6 per share.
Nvidia's update at CES, February's expected guidance and the March GTC conference are items the analyst is watching going forward. Nvidia is called a top pick by the analyst.
JPM on NVDA: Third-quarter results were solid and the company's guidance shows strong AI demand, Sur said in a new investor note.
"Blackwell production ramp progressing well and demand outstripping supply through majority of CY25," Sur said.
The analyst said demand for Blackwell is "very strong" and highlighted management's commentary on expectations for Hopper shipments to remain strong into 2025 as well.
"Bottom line, the team continues to maintain a 1-2 step lead ahead of competitors with its silicon/hardware/software platforms, and a strong ecosystem and the team is further distancing itself."
Oppenheimer on NVDA: Third-quarter financial results and guidance were roughly inline with buyside expectations, led by Data Center strength, Schafer said in a new investor note.
"NVDA remains best positioned in AI, benefitting from full-stack AI hardware/software," Schafer said.
The analyst said Nvidia is "the purest scale play" for "AI proliferation." &nbsp;
"We see several structural tailwinds driving sustained outsized top-line growth in high-performance gaming, datacenter/AI and autonomous driving vehicles."
Goldman Sachs on NVDA: The ramp in Blackwell and yield improvements are likely to drive earnings per share growth, Hari said in a new investor note.
The analyst said Nvidia's guidance "only met Street expectations" and comments on gross margin headwinds, but the outlook remains strong for the stock.
"We expect growing demand for AI infrastructure across all customer groups," Hari said.
The analyst also expects improving supply and gross margin normalization to help drive earnings per share growth.
Piper Sandler on NVDA: Nvidia beating third-quarter analyst estimates kept up with recent trends, Kumar said in a new investor note.
The analyst said Nvidia is setting up for strong growth starting in April.
"The key here is that NVDA is going through a product transition with Blackwell ramping and H200 remaining strong," Kumar said.
Nvidia's guidance beats could be higher starting in April, Kumar added.
"All systems go for Blackwell ramp."
Needham on NVDA: The Blackwell ramp is ahead of previous estimates, Bolton said in a new investor note.
The analyst said guidance was below some of the loftier estimates from analysts with third-quarter results well ahead of Needham estimates.
"Management not only silenced the Blackwell overheating rumors, but raised its F4Q Blackwell revenue guide," Bolton said.
The analyst highlighted Nvidia mentioning Blackwell production was full steam ahead while naming customers such as Dell, Oracle, Microsoft, Alphabet and CoreWeave.
"Demand is ‘greatly exceeding supply,' and Blackwell sales for the January quarter are currently on track to exceed previous guidance of several billions of dollars."
Benchmark on NVDA: Third-quarter results had plenty of strength, but the lack of a huge guidance raise left shareholders wanting more and taking profits, Acree said.
"Nothing except the most aggressive beat and raise was likely to keep the market from fairly aggressive profit-taking, which is exactly what happened," Acree said.
The analyst said investors may be getting wary about the longevity of "the AI trade" with Nvidia shares up over 200% year-to-date ahead of earnings.
"The company's performance and outlook appear to be suffering from a "law of large numbers."
Despite Nvidia shares being up over 700% since early 2023 compared to the S&amp;P 500 up 57% over the same time period, the analyst sees long-term value.
"NVDA's shares still represent a compelling value for thoughtful investors willing to look past the near-term noise."
NVDA Price Action: Nvidia stock is down 1.46% to $143.76 on Thursday versus a 52-week trading range of $45.01 to $152.89. Nvidia stock is up 200% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/42111372/dan-ives-predicts-nvidias-blackwell-chips-are-heading-for-massive-demand-trajectory-as-jensen-huang-says-lebron-of-chip-releases-to-surpass-hopper-gpu-shipments">Dan Ives Predicts Nvidia&#8217;s Blackwell Chips Are Heading For &#8216;Massive Demand Trajectory&#8217; As Jensen Huang Says &#8216;LeBron Of Chip Releases&#8217; To Surpass Hopper GPU Shipments</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Reiteration

Tech

Nvidia Analysts See Stock 'Best Positioned In AI,' Not Worried About Guidance: 'All Systems Go For Blackwell Ramp'

WIIM

ADBE

ASAN

BILL

CHKP

DOCN

ESTC

GTLB

HUBS

INTU

OKTA

ORCL

RGTI

TEAM

TWLO

WDAY

Shares of software, cybersecurity, and cloud companies are trading higher in possible sympathy with Snowflake, which saw gains after the company reported better-than-expected Q3 financial results and raised its FY25 product revenue guidance.

Embecta Corporation (EMBC) has provided an update. Embecta Corp. has announced the resignation of Brian Capone, the Chief Accounting Officer, effec...

Embecta Corporation Announces Chief Accounting Officer Resignation

The medtech industry's long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Amid this backdrop, investors could consider investing in sound medtech stocks Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>), Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>) which are poised for high-growth.
Technology has revolutionized the healthcare segment with cutting-edge devices and innovations resulting in enhanced outcomes, lower costs, and improved access to care. These innovations led to <a href="https://www.marketsandmarkets.com/blog/HC/The-Global-MedTech-Industry-Outlook-2024#:~:text=The%20global%20MedTech%20sales%20are,to%20outgrow%20the%20US%20market.">FDA approvals of 171 artificial intelligence and machine learning</a> (AI/ML)-enabled medical devices for human use. Also, Generative AI and AI-enabled devices in medtech will remain in focus this year.
The medical technology market revenue is projected to reach $598.90 billion in 2024 worldwide with medical devices market likely to dominate. The medical technology market is <a href="https://www.statista.com/outlook/hmo/medical-technology/worldwide">expected to grow at a CAGR of 5.3%</a>, resulting in a market volume of $775.80 billion by 2029. The US is poised to generate highest revenue of $210 billion by 2024 due to increased investment in R&amp;D.
Further, with AI driving innovation in diagnostics, personalized care, and operational efficiency, the <a href="https://www.medicaldevice-network.com/data-insights/artificial-intelligence-in-medical/?cf-view">artificial intelligence in the medical device industry</a> is flourishing. Medical companies are increasingly adopting AI technologies to enhance their operations and patient care. The market is poised to grow to $97.07 billion by 2028, growing at a <a href="https://blog.marketresearch.com/artificial-intelligence-in-medical-devices-market-set-for-unprecedented-growth">CAGR of 44.4%</a>.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, beginning with the third choice.
Stock #3: Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>)
BAX develops and provides a portfolio of healthcare products worldwide. The company operates in four segments: Medical Products and Therapies; Healthcare Systems and Technologies; Pharmaceuticals; and Kidney Care.
On August 13, BAX and funds managed by global investment firm Carlyle (<a href="https://stocknews.com/stock/CG/">CG</a>) signed a definitive agreement under which Carlyle will acquire BAX's Kidney Care segment, to be named Vantive, for $3.80 billion.
The transaction marks a key milestone in BAX's ongoing business transformation, allowing heightened strategic clarity, operational efficiency and innovation. It also provides increased flexibility to deploy capital toward opportunities to accelerate Baxter's and Vantive's respective growth objectives
On July 30, BAX launched the Helion Integrated Surgical System in Thailand. With the help of operating room integration and cutting-edge technology, Helion simplifies operating rooms to help healthcare institutions in Thailand boost OR efficiency and keeping surgical teams focused and connected.
BAX's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.8% year-over-year to $3.81 billion for the second quarter that ended June 30, 2024. The company's adjusted operating income grew 6.7% from the year-ago value to $522 million. Adjusted net income attributable to Baxter stockholders and adjusted EPS came in at $345 million and $0.68, indicating growth of 3% year-over-year, respectively.
As per the company guidance, BAX expects sales growth of 4% - 5% and adjusted EPS of $0.77 - $0.79 for the third quarter 2024. Further, for the full fiscal 2024, it expects sales growth of 3% and its adjusted EPS is expected to range between $2.93 and $3.01.
Street expects BAX's revenue and EPS for the third quarter (ending September 2024) to increase 3.6% and 14.1% year-over-year to $3.84 billion and $0.78, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
BAX's stock has increased 6.4% over the past month to close the last trading session at $37.54.
BAX's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Growth and a B grade for Value. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, BAX is ranked #27 out of 135 stocks.
<a href="https://stocknews.com/stock/BAX/">Click here</a> to access additional ratings of BAX for Momentum, Sentiment, Quality, and Stability.
Stock #2: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. The company designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed a definitive agreement to acquire OrthoGrid Systems, Inc., a privately-held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform Hip AI&#xAE;, and its FDA-cleared orthopedic applications and over 40 patents.
The strategic acquisition will expand ZBH's hip portfolio with artificial intelligence-driven surgical guidance system.
On June 12, ZBH and RevelAi Health entered into a multi-year co-marketing agreement to commercialize generative AI-powered engagement solutions to advance value-based orthopedic care and health equity. Under the agreement, ZBH Biomet will commercialize RevelAi Health's patient care-management platform, care team dashboard for providers, and any future products or services.
ZBH's revenue and EBITDA have grown at respective CAGRs of 0.7% and 3.3% over the past three years. The company's EBIT has increased 6.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 2.9% and 3%, respectively.
During the second quarter that ended on June 30, 2024, ZBH's net sales increased 3.9% year-over-year to $1.94 billion, and its adjusted gross profit increased 3.3% year-over-year to $1.39 billion. The company's adjusted operating profit grew 7.4% from the year-ago value to $552.60 million.
In addition, net earnings of ZBH and EPS came in at $242.80 million and $1.18, reflecting increases of 15.8% and 18% from the prior year's quarter, respectively.
As per the company guidance for the full year 2024, ZBH expects revenue change of 4.0% - 5.0% and its adjusted EPS is expected between $8 and $8.15.
Analysts expect ZBH's revenue for the third quarter (ending September 2024) to grow 4.7% year-over-year to $1.84 billion and its EPS for the same period is expected to increase 9.3% year-over-year to $1.80. Furthermore, the company surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
ZBH's shares have gained 4.7% over the past month and marginally over the past year to close the last trading session at $115.05.
ZBH's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value, Growth, and Quality. Within the Medical – Devices &amp; Equipment industry, ZBH is ranked #24 out of 135 stocks.
In addition to the POWR Ratings we've stated above, we also have ZBH ratings for Stability, Momentum, and Sentiment. Get all ZBH ratings <a href="https://stocknews.com/stock/ZBH/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a medical device company which focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. The company's portfolio include pen needles, syringes, and safety injection devices, and digital applications to assist people with managing patient's diabetes.
On August 9, EMBC's Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of its common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.
EMBC pays an annual dividend of $0.60, which translates to a yield of 4.29% at the current share price. Its four-year average dividend yield is 2.33%.
EMBC reported revenues of $272.50 million for the third quarter that ended June 30, 2024, and its adjusted gross profit grew marginally from the year-ago value to $190.30 million. The company's adjusted operating income of $83.30 million indicates a growth of 4.4% from the prior year's quarter.
Furthermore, the company's adjusted net income came in at $43 million and $0.74 per share, up 8% and 7.2% year-over-year, respectively.
As per the company's fiscal year 2024 outlook, EMBC expects its revenues between $1.11 billion and $1.12 billion. The company also revised its adjusted EPS to range from $2.30 to $2.35, compared to the previous guidance of $2.20 - $2.30.
Street expects EMBC's revenue for the fiscal year 2024 (ending September 2025) to increase marginally year-over-year to $1.12 billion and its EPS for the same year is expected to be $2.26. Also, the company has topped the consensus revenue and EPS estimate in all four trailing quarters, which is remarkable.
Shares of EMBC have surged 7.8% over the past three months to close the last trading session at $14.
EMBC's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
EMBC has an A grade for Value and Quality. It also has a B for Growth. The stock has topped among the 135 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have EMBC ratings for Sentiment, Momentum, and Stability. Get all EMBC ratings <a href="https://stocknews.com/stock/EMBC/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $115.26 per share on Monday afternoon, up $0.21 (+0.18%). Year-to-date, ZBH has declined -4.90%, versus a 18.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-bax-embc-cg-3-high-growth-medtech-stocks-to-buy/>3 High-Growth MedTech Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth MedTech Stocks to Buy

Embecta gets FDA clearance for type 2 diabetes patch pump

Morgan Stanley analyst Kallum Titchmarsh maintained a Sell rating on Embecta Corporation (EMBC – Research Report) yesterday and set a price target ...

Recommendation to Sell: Anticipated Costs and Competition Challenge Embecta's New Pump Program

In a report released yesterday, Marie Thibault from BTIG reiterated a Hold rating on Embecta Corporation (EMBC – Research Report). The company's sh...

BTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)

Embecta Corp.: Navigating Through A Changing Landscape

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more… Thanks to cutting-edge technology, medical stocks are effectively reshaping the healthcare sector. The industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics, surgeries, and patient monitoring.
Given this backdrop, investors looking for growth opportunities could take a look at these three fundamentally robust medical device stocks: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>). These companies are shaping healthcare delivery's future and benefitting from technological advancements.
The medical devices industry is poised for steady growth as its market size is anticipated to reach <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">$893.07 billion by 2029</a>, exhibiting a CAGR of 7%. Moreover, by 2030, the global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion</a>.
Moreover, innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care. The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, which promise faster diagnoses, more precise treatments, and improved patient outcomes.
Considering these favorable trends, let's look at the fundamentals of the above-mentioned <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks in detail:
Stock #3: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of worldwide diagnostics, medical imaging systems, and surgical products. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies and diversifies HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter.
In addition, its adjusted EBITDA increased 8.5% year-over-year to $338.50 million. HOLX's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with non-GAAP EPS anticipated to fall between $0.97 and $1.04.
The consensus revenue estimate of $977.49 million for the fiscal fourth quarter (ended September 2024) represents a 3.4% increase year-over-year. The consensus EPS estimate of $1.01 for the same quarter indicates a 13.9% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past three and five years, HOLX's total assets grew at CAGRs of 1.2% and 6.4%, respectively. Also, the company's normalized net income and operation income (EBIT) have increased at a CAGR of 16.8% and 10.9%, respectively, over the past five years.
Shares of HOLX have gained 14.3% over the past year to close the last trading session at $79.22.
HOLX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
HOLX has a B grade for Growth and Quality. It is ranked #14 out of 134 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/HOLX/">Click here</a> to see the additional ratings for HOLX (Value, Momentum, Stability, and Sentiment).
 Stock #2: Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>)
AVNS is a medical device company that focuses on delivering medical device solutions. The company conducts its business in one segment, which provides its medical device products to healthcare providers and patients globally with manufacturing facilities.
AVNS' net sales for the second quarter (ended June 30, 2024) increased marginally year-over-year to $171.70 million. Its non-GAAP operating profit from continuing operations grew 18.5% from the prior year's quarter to $21.80 million. The company's net income stood at $1.80 million compared to the prior-year quarter's loss of $68.10 million, while its EPS came in at $0.04 versus a loss of $1.46 per share last year.
In addition, AVNS' adjusted EBITDA from continuing operations rose 17% from the year-ago value to $26.80 million. Its free cash flow came in at $21.90 million compared to a year-ago net loss of $6.6 million.
As per the fiscal year 2024 outlook, AVNS forecasts revenue from continuing operations to range between $685 million and $705 million. The company also expects adjusted EPS from continuing operations between $1.30 and $1.45 and adjusted gross margins from continuing operations to fall in the range of 59.5%-60.5%.
Street expects AVNS' revenue for the fiscal third quarter (ended September 2024) to increase 2.4% year-over-year to $175.33 million. Its EPS for the same period is expected to register a 17.8% growth from the prior year, settling at $0.35. In addition, it surpassed the consensus revenue in each of the trailing four quarters, which is promising.
Moreover, AVNS' EBITDA and net income have grown at CAGRs of 32.7% and 47.5%, respectively, over the past three years. In addition, its EPS increased at 60.6% CAGR over the same time frame.
Over the past three months, the stock has surged 18.5%, closing the last trading session at $23.02.
It's no surprise that AVNS has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value. Out of 134 stocks in the same industry, AVNS is ranked #12.
Beyond what is stated above, we've also rated AVNS for Momentum, Stability, Sentiment, and Quality. Get all AVNS ratings <a href="https://stocknews.com/stock/AVNS/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a global diabetes care company focusing on providing various solutions to enhance the health and well-being of people with diabetes. It has a portfolio of products that include pen needles, syringes, safety injection devices, and digital applications to assist people with managing patient's diabetes. 
On September 3, EMBC received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system, required for adults who require insulin, both type 1 (T1D) and type 2 (T2D) diabetes, to be managed. This clearance aligns with the company's vision and focuses on developing a patch pump, addressing obstacles to adopting pump therapy for people who use insulin daily to manage their diabetes. 
For the third quarter of 2024, which ended on June 30, EMBC's revenue stood at $272.50 million. Its adjusted operating income grew 4.4% from the year-ago value to $83.30 million. Its adjusted net income for the quarter amounted to $43 million or $0.74 per share, representing an increase of 8% and 7.2%, respectively, from the same period last year. Also, the company reported an adjusted EBITDA of $99.20 million, indicating a 15.5% growth from the prior year's quarter.
The company has updated its fiscal year 2024 financial guidance, increasing its adjusted gross margin projection to a range of 65.25% to 65.50%, up from the previous estimate of 64.5% to 65%. Additionally, it adjusted its non-GAAP EPS guidance to a new range of $2.30 to $2.35, slightly higher than the prior forecast of $2.20 to $2.30.
Moreover, its adjusted EBITDA margin is expected to range between 31.25%-31.50%, an increase from the previous estimate of 31%-31.5%. Meanwhile, EMBC projects its revenue to fall in the range of $1.11 billion to $1.12 billion.
Analysts expect EMBC's revenue and EPS for the current year (ending September 2024) to be $1.11 billion and $2.39, respectively. For the fiscal year 2025, its revenue is expected to grow marginally from the prior year to $1.12 billion, and its EPS is projected to come in at $2.27.
Over the past year, EMBC's net income has increased at a CAGR of 47.7%, while its EPS grew at 45.3% CAGR.
EMBC shares have surged 10.1% over the past three months to close the last trading session at $13.29.
EMBC's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Medical - Devices &amp; Equipment industry, it is ranked #3. <a href="https://stocknews.com/stock/EMBC/">Click here</a> to see EMBC's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HOLX shares were trading at $79.88 per share on Friday morning, up $0.66 (+0.83%). Year-to-date, HOLX has gained 11.80%, versus a 20.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/holx-avns-embc-3-medical-device-stocks-with-strong-growth-prospects/>3 Medical Device Stocks With Strong Growth Prospects</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks With Strong Growth Prospects

AVNS

HOLX

PODD

TNDM

Press Releases

embecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir

embecta to Report Fiscal Third Quarter 2024 Financial Results

Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company

Dividends

embecta Announces Quarterly Cash Dividend

Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results

embecta to Participate in Investor Events

embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes

embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell

embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

Comments

Embecta

Embecta (EMBC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga